IL254124A0 - New 3-indole-transformed histories, medicinal preparations and methods of use - Google Patents
New 3-indole-transformed histories, medicinal preparations and methods of useInfo
- Publication number
- IL254124A0 IL254124A0 IL254124A IL25412417A IL254124A0 IL 254124 A0 IL254124 A0 IL 254124A0 IL 254124 A IL254124 A IL 254124A IL 25412417 A IL25412417 A IL 25412417A IL 254124 A0 IL254124 A0 IL 254124A0
- Authority
- IL
- Israel
- Prior art keywords
- novel
- methods
- pharmaceutical compositions
- substituted derivatives
- indol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2015/051957 WO2015140717A1 (en) | 2014-03-18 | 2015-03-17 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| US201562203032P | 2015-08-10 | 2015-08-10 | |
| PCT/IB2016/051509 WO2016147144A1 (en) | 2015-03-17 | 2016-03-17 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL254124A0 true IL254124A0 (en) | 2017-10-31 |
Family
ID=56919874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254124A IL254124A0 (en) | 2015-03-17 | 2017-08-23 | New 3-indole-transformed histories, medicinal preparations and methods of use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9873690B2 (enExample) |
| EP (1) | EP3271354A1 (enExample) |
| JP (1) | JP6775516B2 (enExample) |
| KR (1) | KR102013512B1 (enExample) |
| CN (1) | CN107635990A (enExample) |
| AU (1) | AU2016231832B2 (enExample) |
| BR (1) | BR112017019699A2 (enExample) |
| CA (1) | CA2979616C (enExample) |
| HK (1) | HK1243999A1 (enExample) |
| IL (1) | IL254124A0 (enExample) |
| MX (1) | MX2017011951A (enExample) |
| RU (1) | RU2672252C1 (enExample) |
| SG (1) | SG11201706992TA (enExample) |
| WO (1) | WO2016147144A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015179225A1 (en) | 2014-05-18 | 2015-11-26 | Yeh Alexander Jueshyan | Midfield coupler |
| US20160336813A1 (en) | 2015-05-15 | 2016-11-17 | NeuSpera Medical Inc. | Midfield coupler |
| WO2016187594A1 (en) | 2015-05-21 | 2016-11-24 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| CA3060989A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN111166735B (zh) * | 2020-01-15 | 2023-08-18 | 延边大学 | 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用 |
| CN111499592B (zh) * | 2020-03-14 | 2023-06-23 | 江苏省农用激素工程技术研究中心有限公司 | 5-氨甲基糖精的合成方法 |
| KR102574950B1 (ko) * | 2020-04-30 | 2023-09-06 | 메드샤인 디스커버리 아이엔씨. | 벤조술탐 함유 화합물 |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| CN111777557B (zh) * | 2020-07-28 | 2022-11-22 | 中国科学院上海有机化学研究所 | 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用 |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| EP4490191A1 (en) | 2022-03-08 | 2025-01-15 | Alentis Therapeutics AG | Use of anti-claudin-1 antibodies to increase t cell availability |
| AU2023393653A1 (en) | 2022-12-14 | 2025-05-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025252553A1 (en) | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| CN119707855A (zh) * | 2024-12-20 | 2025-03-28 | 西南大学 | 一种光学活性胺类衍生物及其不对称烷基化合成方法和应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509731C2 (sv) | 1996-05-14 | 1999-03-01 | Labwell Ab | Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi |
| JP2000095759A (ja) | 1998-07-21 | 2000-04-04 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および剤 |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| JP2005507922A (ja) | 2001-09-19 | 2005-03-24 | ファルマシア・コーポレイション | 炎症の治療のための置換されたインダゾール化合物 |
| DE60331219D1 (de) | 2002-03-28 | 2010-03-25 | Eisai R&D Man Co Ltd | Azaindole als hemmstoffe von c-jun n-terminalen kinasen |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| FR2845996A1 (fr) | 2002-10-16 | 2004-04-23 | Servier Lab | Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7714139B2 (en) * | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| CN1795187A (zh) * | 2003-03-27 | 2006-06-28 | 兰肯瑙医学研究所 | 新型ido抑制剂及其使用方法 |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| GB0328909D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| US7405215B2 (en) * | 2004-09-21 | 2008-07-29 | Wyeth | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof |
| WO2006086484A1 (en) | 2005-02-09 | 2006-08-17 | Arqule, Inc. | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
| WO2007039580A1 (en) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted benzophenone compounds |
| WO2007045622A1 (en) | 2005-10-18 | 2007-04-26 | Nycomed Gmbh | Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors |
| WO2007050963A1 (en) * | 2005-10-27 | 2007-05-03 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use thereof |
| AU2007208109B2 (en) | 2006-01-24 | 2012-08-23 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
| EP2001480A4 (en) | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| KR20080108517A (ko) | 2006-04-05 | 2008-12-15 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| GB0624308D0 (en) | 2006-12-05 | 2007-01-17 | Molmed Spa | Combination product |
| MX2009005934A (es) | 2006-12-07 | 2009-06-17 | Novartis Ag | Compuestos organicos. |
| CA2677096A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| US8389568B2 (en) * | 2007-03-16 | 2013-03-05 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| JP2010534665A (ja) | 2007-07-25 | 2010-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用 |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| CN101983384A (zh) | 2007-11-30 | 2011-03-02 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
| US8222424B2 (en) | 2008-03-24 | 2012-07-17 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| WO2010008427A1 (en) | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
| NZ590268A (en) * | 2008-07-08 | 2012-11-30 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| SG171815A1 (en) | 2008-12-19 | 2011-07-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| WO2010096389A1 (en) | 2009-02-17 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
| US8158625B2 (en) | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| CA2775133A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
| CN102573478B (zh) | 2009-10-12 | 2015-12-16 | 拜尔农作物科学股份公司 | 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑 |
| EP2488486B1 (en) | 2009-10-13 | 2019-08-14 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| US20140243324A1 (en) | 2010-11-18 | 2014-08-28 | Ligand Pharmaceuticals Incorporated | Use of hematopoietic growth factor mimetics |
| MX2013010771A (es) | 2011-03-22 | 2014-01-31 | Amgen Inc | Compuestos de azoles como inhibidores. |
| KR101581522B1 (ko) | 2011-05-23 | 2015-12-31 | 메르크 파텐트 게엠베하 | 피리딘 및 피라진 유도체 |
| JP2014521749A (ja) | 2011-08-17 | 2014-08-28 | アムジエン・インコーポレーテツド | ヘテロアリールナトリウムチャネル阻害剤 |
| US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| JP2017505346A (ja) | 2014-02-12 | 2017-02-16 | アイティーオス セラペウティクス | 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法 |
| EP3119763A1 (en) * | 2014-03-18 | 2017-01-25 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| US20150266857A1 (en) * | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| MD20160118A2 (ro) | 2014-05-15 | 2017-04-30 | Iteos Therapeutics | Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1 |
| EP3334733A1 (en) * | 2015-08-10 | 2018-06-20 | Pfizer Inc | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
-
2016
- 2016-03-17 EP EP16711022.0A patent/EP3271354A1/en not_active Withdrawn
- 2016-03-17 CA CA2979616A patent/CA2979616C/en not_active Expired - Fee Related
- 2016-03-17 BR BR112017019699-9A patent/BR112017019699A2/pt not_active Application Discontinuation
- 2016-03-17 AU AU2016231832A patent/AU2016231832B2/en not_active Ceased
- 2016-03-17 WO PCT/IB2016/051509 patent/WO2016147144A1/en not_active Ceased
- 2016-03-17 HK HK18103418.8A patent/HK1243999A1/zh unknown
- 2016-03-17 KR KR1020177029203A patent/KR102013512B1/ko not_active Expired - Fee Related
- 2016-03-17 CN CN201680028408.7A patent/CN107635990A/zh active Pending
- 2016-03-17 RU RU2017130845A patent/RU2672252C1/ru not_active IP Right Cessation
- 2016-03-17 MX MX2017011951A patent/MX2017011951A/es unknown
- 2016-03-17 JP JP2017548261A patent/JP6775516B2/ja not_active Expired - Fee Related
- 2016-03-17 US US15/072,534 patent/US9873690B2/en not_active Expired - Fee Related
- 2016-03-17 SG SG11201706992TA patent/SG11201706992TA/en unknown
-
2017
- 2017-08-23 IL IL254124A patent/IL254124A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102013512B1 (ko) | 2019-08-22 |
| CA2979616C (en) | 2020-04-28 |
| CN107635990A (zh) | 2018-01-26 |
| KR20170132204A (ko) | 2017-12-01 |
| AU2016231832A1 (en) | 2017-09-14 |
| HK1243999A1 (zh) | 2018-07-27 |
| US9873690B2 (en) | 2018-01-23 |
| SG11201706992TA (en) | 2017-09-28 |
| EP3271354A1 (en) | 2018-01-24 |
| MX2017011951A (es) | 2018-06-15 |
| JP2018511587A (ja) | 2018-04-26 |
| BR112017019699A2 (pt) | 2018-09-04 |
| JP6775516B2 (ja) | 2020-10-28 |
| AU2016231832B2 (en) | 2019-09-19 |
| RU2672252C1 (ru) | 2018-11-13 |
| WO2016147144A1 (en) | 2016-09-22 |
| CA2979616A1 (en) | 2016-09-22 |
| US20160272628A1 (en) | 2016-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254124A0 (en) | New 3-indole-transformed histories, medicinal preparations and methods of use | |
| IL254714B (en) | History of quinoline and pharmaceutical preparations containing them | |
| IL258082B (en) | History of benzaimidazole and pharmaceutical preparations containing them | |
| IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
| PT3643709T (pt) | Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos | |
| IL250422A0 (en) | History of pyrrolidinone, and pharmaceutical preparations containing them | |
| IL258160B (en) | Biaryl derivatives, pharmaceutical preparations containing them and their uses | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| EP3381925A4 (en) | Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof | |
| IL249308B (en) | The history of quinoline, their preparation and pharmaceutical preparations containing them | |
| LT3223796T (lt) | Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| IL248773B (en) | History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| EP3284743A4 (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
| GB201811142D0 (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
| LT3229843T (lt) | Farmacinė kompozicija, jos paruošimo būdas ir naudojimas | |
| PL3313370T3 (pl) | Okulistyczna kompozycja farmaceutyczna | |
| IL258977B (en) | Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| IL257621B (en) | A catechol derivative and a pharmaceutical preparation that includes it | |
| PL3386988T3 (pl) | Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| HUE059610T2 (hu) | Gyógyszerészeti készítmény, amely indolszármazékokat tartalmaz, valamint eljárás annak elõállítására és felhasználására | |
| IL259900A (en) | Aminoazole derivatives, compositions containing same and uses thereof |